A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease
Table 1
Clinical and serological characteristics of the study population.
Factor
All subjects ()
Non-NASH ()
NASH ()
value
Age (years)
39.80 ± 11.21
38.00 ± 10.56
41.4 ± 11.68
0.219
Gender (M/F)
50/15
24/7
26/8
0.928
ALT (u/L)
73.24 ± 62.50
55.52 ± 49.49
89.41 ± 69.17
AST (u/L)
29.86 ± 27.47
26.71 ± 30.34
32.74 ± 24.69
0.381
GGT (iu/L)
42.35 ± 20.71
37.64 ± 18.21
46.64 ± 21.15
0.080
Tbil (umol/L)
14.92 ± 6.05
14.06 ± 5.50
15.71 ± 6.50
0.275
TC (mmol/L)
4.35 ± 1.03
4.25 ± 0.99
4.45 ± 1.07
0.437
TG (mmol/L)
1.71 ± 0.55
1.53 ± 0.44
1.87 ± 0.88
FBG (mmol/L)
5.19 ± 0.81
4.80 ± 0.64
5.54 ± 0.79
Lg10 (HBVDNA)
5.00 ± 2.16
4.75 ± 2.12
5.23 ± 2.20
0.371
HBeAg positive ()
25
16
9
CK-18 M30 (u/L)
569.60 + 429.54
345.13 ± 136.13
774.26 ± 500.49
LSM (Kpa)
8.62 ± 4.59
7.63 ± 4.16
9.53 ± 4.83
0.095
CAP (dBm−1)
270.92 ± 45.70
243.10 ± 31.12
296.28 ± 42.19
, . , number; M, male; F, female; value corresponds to the comparison of the two groups. ALT, alanine aminotransferase; AST, aspartic transaminase; r-GT, r-glutamine transpeptidases; TBil, total bilirubin; TG, triglyceride; TC, total cholesterol; FBG, fasting blood-glucose; LSM, liver stiffness measurement; CAP, controlled attenuation parameter.
